Clifton Bingham, MD and Vicky Ruffing, RN discuss the Seasonal and Novel N1N1 flu and potential impact on the rheumatology community. Information is focused on the immunizations, delivery systems, and targeted populations.
Johns Hopkins Arthritis Center
Associate Professor of Medicine
Director - Johns Hopkins Arthritis Center
Clifton Bingham, MD and Vicky Ruffing, RN discuss the Seasonal and Novel N1N1 flu and potential impact on the rheumatology community. Information is focused on the immunizations, delivery systems, and targeted populations.
Tofacitinib (Xeljanz®) is the first of a unique class of oral kinase inhibitors to be FDA approved for the treatment of rheumatoid
Depression and anxiety are more common among individuals with arthritis than among the general population. Yet, these mood disorders are
TNFα inhibitors have demonstrated great efficacy for the treatment of rheumatoid arthritis (RA). However, they are not without potential
Copyright Johns Hopkins Arthritis Center © 2013